Altramet

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Altramet

Quick Facts

Property Description
Active ingredient Cimetidine
Form Tablet, Oral solution, Injection
Pharmacological class Histamine H2-receptor antagonist (H2-blocker)
Common purpose Systemic reduction of gastric acid secretion
Origin Synthetic compound

Altramet is a foundational, synthetic prescription drug primarily used to control and reduce the production of acid in the stomach. The medication's identity is defined by its sole active ingredient, Cimetidine, which is formally classified as a Histamine H2-receptor antagonist or H2-blocker. This classification confirms the drug's established role in modulating gastric function, a property clinically recognized for its rapid onset of action compared to some older gastric therapies.


What Type of Medicine is Altramet (Cimetidine)?

Altramet is classified pharmacologically as an H2-blocker because its mechanism of action involves competitive receptor antagonism. Cimetidine is a single-ingredient product, identified chemically as a substituted imidazole derivative, verifying its synthetic compound origin. This composition is manufactured into several primary dosage forms, including the tablet and oral solution for oral administration, as well as a preparation for parenteral injection, providing a versatile systemic application. Research consistently describes the primary action as suppressing acid output induced by histamine and other stimuli, which has been confirmed across multiple independent pharmacological studies.


Altramet’s General Purpose and Available Forms

The primary purpose of Altramet is to mitigate the effects of gastric acid hypersecretion by systemically reducing the volume and concentration of acid released into the digestive tract. This capability is leveraged in clinical scenarios, such as when patients require reliable management of chronic nocturnal acid output. The general benefit is achieved because Cimetidine works by blocking specific H2 receptors on the stomach's parietal cells, effectively inhibiting the signal that triggers acid production. The drug’s availability as a tablet, oral solution, and injection ensures that its acid-reducing action can be delivered effectively through various routes, making it a reliable agent for stabilizing the gastric environment and controlling excess acidity.

What side effects are possible with Altramet?

Possible Side Effects and Safety Information

The safety profile for Altramet (Cimetidine) is defined by officially documented adverse reactions classified by their frequency and the physiological systems affected, according to regulatory standards.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence in clinical use:

  • Common Reactions: These include nervous system effects such as headache and dizziness, as well as gastrointestinal effects like diarrhoea. Other common reactions include tiredness, skin rashes, and myalgia (muscle pain).
  • Uncommon Reactions: Psychiatric disorders such as confusional states, depression, and hallucinations are noted. Other uncommon effects involve the blood (leukopenia), hepatobiliary system (hepatitis), and reproductive system (gynaecomastia, reversible impotence).
  • Rare and Very Rare Reactions: Clinically significant reactions documented as rare or very rare include serious blood disorders like agranulocytosis and aplastic anaemia, cardiac issues such as heart block or sinus bradycardia, and immune responses like anaphylaxis.

Safety Considerations in Specific Contexts

Official labeling provides specific safety context related to certain patient groups and exposure patterns:

  • Population-Specific Risk: Confusional states are reported predominantly in the elderly, severely ill patients, or those with pre-existing renal or hepatic impairment. These effects are generally noted to be reversible upon discontinuing the medication.
  • Exposure Patterns: Certain effects, including gynaecomastia and reversible impotence, are reported in association with high doses or long-term exposure. Additionally, confusional states may typically develop within the first few days of treatment initiation.
  • Laboratory Measures: The medication may cause a small, non-progressive increase in plasma creatinine that is related to competition for renal excretion and does not signify deteriorating renal function.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Altramet (Cimetidine) based on documented clinical manifestations and mandated emergency actions. Excessive ingestion may lead to specific systemic signs across multiple physiological systems.

Documented Overdose Manifestations

System Manifestation
Cardiovascular Tachycardia, Sinus bradycardia, Heart block
Central Nervous System Confusion, Fever
Respiratory Shortness of breath, Bronchospasm

Serious outcomes are classified as potentially life-threatening, particularly respiratory failure and critical compromise to cardiovascular status. Specific consideration is given to the elderly and patients with impaired renal function due to an increased risk of CNS adverse effects being exacerbated during overdose.

Emergency Response and Management

Regulators mandate that individuals seek emergency medical attention immediately and contact a Poison Control Center for any suspected overdose. No specific antidote is known for Cimetidine. Management is strictly limited to symptomatic and supportive treatment, including maintaining the airway and continuous close monitoring of the patient's cardiovascular status.

Therapeutic Uses of Altramet

What Altramet Treats: Main Uses and Benefits

Altramet is a medication that may be part of symptomatic management, applied across domains where additional symptomatic support is needed. The medication is used for symptomatic relief, addressing disruptive manifestations of the condition.


Easing Acute Symptom Burdens

Altramet is generally used in situations involving certain distressing symptoms, applied in contexts where additional symptomatic support for pain management is needed. It is commonly used to help with pain management, particularly for symptoms related to physical discomfort. It is considered relevant in contexts marked by increased discomfort or tension. It contributes to improved comfort during periods of heightened symptoms and may help patients cope more steadily with symptom fluctuations.

“The medication supports patients during episodes of heightened discomfort.”

Supportive Management and Functional Strain

This medication is relevant in conditions characterized by periods of heightened symptoms and often used during phases when symptoms become more noticeable. Altramet may assist in addressing symptom clusters that may become intense or disruptive, such as symptoms that interfere with daily functioning and symptoms that create noticeable physiological strain. The application supports general well-being during symptomatic phases and provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Acute Discomfort Altramet is commonly used when short-term symptomatic assistance is needed to manage discomfort associated with acute or episodic changes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory documents define specific populations allowed to use Altramet (Cimetidine) and those who must not use it due to absolute contraindications or high-risk status.

Classification Population or Condition
Absolutely Contraindicated Patients with a known hypersensitivity or allergy to Cimetidine [Source 1.2] and those receiving the antiarrhythmic drug dofetilide [Source 3.3].
Conditional or Restricted Use Patients with impaired renal function (Creatinine Clearance < 50 mL/min) must use a reduced dose [Source 2.3]. Use requires caution in the elderly and severely ill patients, especially those with pre-existing liver or kidney problems [Source 1.4].
Age-Group Eligibility Use is established in adults [Source 1.1] and adolescents (12 and over) for over-the-counter use [Source 1.2]. For children under 12 years of age, professional consultation is required [Source 1.2].
Reproductive Status The medication is classified as Pregnancy Category B by the FDA, indicating limited risk [Source 4.1]. However, breastfeeding is not recommended by some authorities as Cimetidine is excreted into human milk [Source 4.1].

Eligibility also requires that a malignancy be excluded before starting therapy for any gastric ulceration, as Cimetidine may mask the symptoms of gastric cancer [Source 2.2]. The use of over-the-counter formulations is prohibited for self-medication in patients with acute, severe symptoms such as bloody stools or vomiting with blood [Source 1.2].

What should I know about interactions with other medicines?

Altramet Interactions with other medicines and products

Altramet (Cimetidine) is officially documented to have clinically significant interactions with numerous medicinal products, primarily by inhibiting the elimination of co-administered drugs. The regulatory profile dictates formal contraindications for combinations with agents like Dofetilide, Pimozide, Lomitapide, and Fezolinetant due to the risk of greatly increased drug levels and severe toxicity, such as QTc interval prolongation.

Mechanism of Interaction Affected Drug Categories
Inhibition of CYP Enzymes Anticoagulants (e.g., Warfarin), Anti-epileptics (e.g., Phenytoin), Anti-asthmatics (e.g., Theophylline), and certain Antidepressants.
Inhibition of Renal Excretion Antiarrhythmics (e.g., Dofetilide), Metformin, Procainamide.
Gastric pH Elevation Antifungals (e.g., Ketoconazole), where reduced absorption may occur.

Cimetidine is a documented inhibitor of several Cytochrome P450 (CYP) isoenzymes (including CYP1A2, CYP2C9, CYP2D6, and CYP3A4), which is the basis for reduced clearance and increased plasma exposure of many co-administered substances. This documented inhibition of metabolism and renal tubular secretion results in the requirement for close monitoring. Population-specific notes document that liver disease and renal dysfunction are factors associated with an increased risk of Cimetidine-related Central Nervous System toxicity.

Mechanism of Action

How Altramet Works: Mechanism of Action

Antagonism of Histamine H2 Receptors

Altramet's primary mechanism involves acting as a competitive antagonist at the histamine H2 receptors located on the gastric parietal cells. By occupying these receptors, the molecule blocks the binding of endogenous histamine. This molecular interference disrupts the associated intracellular signaling cascade, which normally leads to the activation of the gastric proton pump ( H^+ / K^+-ATPase). The resulting reduction in upstream signaling limits the final stage of acid extrusion, leading to a measurable reduction in gastric fluid volume and acidity.

Inhibition of Hepatic Cytochrome P450 Enzymes

The drug also engages a distinct mechanistic domain by acting as a powerful inhibitor of several Cytochrome P450 (CYP) enzymes in the liver, notably CYP1A2, CYP2D6, and CYP3A4. This activity slows the oxidative metabolism process, resulting in a slower rate of metabolism and clearance for other compounds that are substrates for these enzymes, thereby increasing their systemic exposure.

Antagonism of the Androgen Receptor

A third, less potent, mechanism involves the drug's weak activity as an antagonist at the Androgen Receptor (AR), which alters downstream androgen signaling.

Dosage and Administration Information

How Altramet is used

Altramet (Cimetidine) is administered according to standardized regimens detailed in official prescribing information. The instructions govern the approved routes of delivery, the precise dosage amounts, and specific conditions for administration, ensuring standardized clinical use.


Administration Routes and Forms

Altramet is available in multiple forms for systemic delivery:

  • Oral: Used for routine management via Tablet (200 mg to 800 mg strengths) or Oral Solution (300 mg/5 mL).
  • Parenteral: Used in acute or hospital settings via Intravenous (IV) or Intramuscular (IM) injection.

Standard Dosing and Schedule

Official adult dosing is based on the specific regimen and indication, with the total daily dose not to exceed 2400 mg:

Regimen Type Typical Adult Dosage Frequency Comments
Oral 800 mg Once daily, at bedtime Common for initial and maintenance use.
Parenteral 300 mg Every 6 -8 hours (IV/IM) Used when oral intake is not feasible.

Administration Requirements

  • Timing: Oral doses are often taken with meals and at bedtime. For preventive use (non-prescription), the medicine is taken up to 30 minutes before eating or drinking.
  • Duration: Initial treatment courses typically last 4 to 8 weeks. Maintenance therapy is approved for longer periods, often using a reduced daily dose (e.g., 400 mg at bedtime).
  • Dose Adjustments: A dose reduction is required for patients with confirmed impaired kidney function (creatinine clearance below 50 mL/minute), as the body clears the drug more slowly.

Recent Clinical Evidence

Research evidence / Overview of studies for Altramet


Evidence for Use in Healing Duodenal and Gastric Ulcers

Research has studied Altramet for the treatment of duodenal and benign gastric ulcers. These investigations were often short-term, randomized controlled trials (RCTs) where the treatment was evaluated in comparison with a placebo or older treatments. The primary outcomes researchers studied were the ulcer healing rate and changes in patient-reported outcomes describing perceived discomfort. The studies observed the healing process over defined time intervals, typically lasting 4 to 8 weeks.

The findings describe patterns observed in the studies where outcomes related to healing measurements were consistently recorded during the short-term evaluation periods. These studies report how symptoms evolved in the observed populations, documenting changes in the frequency and intensity of pain related to the ulcers.


Studies of Long-Term Ulcer Management (Maintenance Therapy)

Research explored the need for continued therapy beyond the initial healing phase through long-term, placebo-controlled studies. These trials monitored patients who had successfully achieved healing to determine the frequency of ulcer recurrence when continued therapy was studied for effectiveness versus when a placebo was given. The observation periods often spanned 6 months to 1 year.

The research describes the recurrence rates observed in study groups over these extended periods. However, long-term effects are not fully established beyond these observation windows. Optimal criteria for identifying patients who discontinued treatment are not uniformly defined across the available research.


Evidence in Special Populations and Research Gaps

Research was studied for use in patient groups outside of typical adult cohorts, specifically in critically ill patients (for GI bleeding prophylaxis) and children. In the critically ill population, studies monitored outcomes related to stress-related bleeding, while research in children was studied for adjunct therapy in limited contexts. Evidence is limited for these special populations.

Comparative evidence is lacking in large-scale trials against newer acid-reducing agents. Finally, research does not determine whether an individual will respond similarly to the group patterns observed; the findings contribute to the broader evidence landscape but do not provide individual predictions.

Key Studies & References

  1. CIMETIDINE TABLETS, USP (Full Prescribing Information)
  2. Cimetidine: Uses & Side Effects - NIH StatPearls (Review of therapeutic applications and evidence context)
  3. Cimetidine for stress-ulcer prophylaxis (Review of comparative studies in critically ill patients)

Frequently Asked Questions (FAQ)

Common questions about Altramet (FAQ)


Q: Does Altramet cause [specific common side effect, e.g., weight gain, drowsiness]?

Official regulatory documents show that central nervous system effects, including drowsiness, have been reported in clinical use. However, weight gain is not listed as a common or uncommon side effect in the official product information.


Q: How long does Altramet stay in your system?

According to official pharmacokinetic studies, Altramet is eliminated relatively quickly from the body. The half-life, which is the time it takes for half of the drug to be cleared, is approximately two hours in healthy adults.


Q: What happens if you miss a dose of Altramet?

Official guidance describes a standardized approach to a missed dose: if it is almost time for the next scheduled dose, the prior dose is typically skipped. Taking two doses at the same time is generally advised against.


Q: Can Altramet be taken with common pain relievers like ibuprofen or acetaminophen?

The official regulatory label advises consulting a healthcare professional before combining Altramet with any prescription drug. While common pain relievers are not specifically listed as affected, confirmation from a doctor or pharmacist is described as the appropriate step to confirm compatibility.


Q: Are there any foods or drinks to avoid while using Altramet?

For preventing symptoms, official instructions suggest taking the medicine before consuming foods or drinks that commonly trigger heartburn. Additionally, official precautions indicate that moderate to heavy use of alcohol is generally advised against while using this medication.


Q: Does Altramet interact with common supplements like multivitamins or herbal teas?

Official drug labels typically focus on interactions with other medicinal products. While specific supplements are not listed, the medicine is known to affect liver enzymes and stomach acidity, which has the potential to alter the way other compounds are processed by the body.


Q: Why do official documents list so many potential side effects for Altramet?

The regulatory purpose of official documents is to provide full transparency regarding potential risks. They are required to list every adverse reaction documented from all clinical trials and post-marketing surveillance, classifying them by how often they have been observed.


Q: What are the signs of an allergic reaction to Altramet?

Official safety information documents that severe allergic reactions, which may include the development of hives, difficult breathing, or swelling in the face or throat, warrant immediate medical attention.


Q: Can Altramet affect birth control pills?

Studies and official information indicate that Altramet is known to inhibit certain liver enzymes called Cytochrome P450 enzymes. This action means the drug has the potential to affect the way the body metabolizes and clears some oral contraceptives.


Q: Is there a generic version of Altramet available?

Yes. Altramet is the brand name, and Cimetidine is the generic active ingredient that is officially approved. Generic versions contain the same core medicine and meet the same regulatory quality standards.


Q: Where can I find the official regulatory information for Altramet?

Official prescribing and regulatory documents are published by government health bodies like the FDA. This information is typically made available to the public on their official websites, such as DailyMed and Drugs@FDA.


Q: Does Altramet have a 'black box' warning?

The official FDA labeling for Altramet (Cimetidine) does not include a Black Box Warning. A Black Box Warning is the strictest safety measure placed on a drug to alert the public and prescribers to serious hazards.


Q: Is it normal to feel [vague sensation, e.g., 'a bit strange'] when first starting Altramet?

Official safety information reports that common central nervous system effects include dizziness, tiredness, and headache. In certain populations, rare effects like confusional states may develop, particularly within the first few days of starting treatment.


Q: What happens if I stop taking Altramet suddenly?

Research studies have explored this topic. According to evidence, abruptly stopping the medicine after achieving ulcer healing has been associated with the recurrence of symptoms.


Q: Why is alcohol strongly discouraged when using Altramet?

Official precautions indicate that moderate to heavy use of alcohol is generally advised against while taking this medication. Additionally, Altramet has side effects that affect the central nervous system, and these effects may be enhanced or confused with the effects of alcohol.


Q: If I have [minor existing condition, e.g., high cholesterol], can I still use Altramet?

The regulatory label instructs individuals with pre-existing conditions to consult a healthcare professional before use. Specific conditions mentioned for requiring professional consultation include having kidney disease or liver disease.


Q: Do I need to get blood tests while taking Altramet?

Official safety information notes that Altramet may temporarily affect certain laboratory measures, such as plasma creatinine levels, and has rarely been associated with blood disorders. For these reasons, close monitoring may be required.


Q: Does Altramet interact with caffeine?

Yes. Official information indicates that Cimetidine can inhibit the metabolism of caffeine in the body. This interaction may lead to increased levels of caffeine, which could potentially result in worsened side effects like nervousness or sleeplessness.


Q: Is Altramet used for any conditions other than the main one listed?

According to the official regulatory indications, Altramet is approved for several uses beyond the short-term treatment of ulcers. These include erosive gastroesophageal reflux disease (GERD) and treating pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome.


Q: What does the term 'contraindication' mean for Altramet?

A contraindication is a critical regulatory term that defines a specific situation or condition in which a medicine should not be used because it may cause harm to the patient. For Altramet, this includes known hypersensitivity or taking certain interacting medications.


Q: What should I do if a side effect of Altramet is bothersome?

The regulatory patient label describes conditions that warrant discontinuing use and consulting a doctor. These include if certain symptoms persist, if heartburn continues or worsens, or if the product is needed for a period exceeding 14 days.


Q: What is the difference between the brand name and generic versions of Altramet?

The brand name Altramet and the generic Cimetidine contain the same single active ingredient and are required by regulatory bodies to meet identical quality standards. The primary difference is often cost, with the generic form typically being more affordable.


Q: Can people with a history of [common chronic illness, e.g., heart disease] use Altramet?

The official regulatory label advises patients to ask a doctor before using the product if they have certain serious heart-related symptoms. These include frequent chest pain or heartburn that is accompanied by lightheadedness, sweating, or dizziness.


Q: Does Altramet require a special prescription?

The medicine is available in two forms based on strength and intended use. Higher doses for specific conditions (like ulcers) are available only as a prescription product, while lower doses for heartburn relief are often available over-the-counter (OTC).

How should Altramet be stored and disposed of?

Storage and Disposal Requirements for Altramet (Cimetidine)

Altramet must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with brief temperature excursions permitted up to 30 C. Official regulations require the medicine to be kept in a tight, light-resistant container and protected from excessive moisture and heat, with explicit instruction to keep the container tightly closed.

Child-Safety and Disposal

All Altramet, like all medications, must be kept out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired Altramet should be taken to a drug take-back program or, if unavailable, disposed of in the household trash following regulatory mixing procedures. The medication must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Altramet found in:

A-Z Index: